Prostaglandin E-2-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release

Autor(es)

Nicolete, Roberto ^[1] ; Lima, Karla de Melo ^[2] ; Junior, Jose M. R. ^[2] ; Jose, Peter J. ^[3] ; Sanz, Maria-Jesus ^{[3, 4]} ; Faccioli, Lucia Helena ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Anal Clin, BR-14040903 Ribeirao Preto - Brazil

^[2] Nanocore Biotecnol Ltda, Campinas, SP - Brazil

^[3] Univ Valencia, Dept Pharmacol, Valencia - Spain

^[4] Spanish Minist Health, Carlos Hlth Inst 3, Madrid - Spain

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS; v. 70, n. 3, p. 784-790, NOV 2008.
• Citações Web of Science: 7

Resumo

PGE(2), an arachidonic acid metabolite produced by various type of cells regulates a broad range of physiological activities in the endocrine, cardiovascular, gastrointestinal, and immune systems, and is involved in maintaining the local homeostasis. In the immune system, PGE(2) is mainly produced by APCs and it can suppress the Th1-mediated immune responses. The aim of this study was to develop PGE(2)-loaded biodegradable MS that prolong and sustain the in vivo release of this mediator. An o/w emulsion solvent extraction-evaporation method was chosen to prepare the MS. We determined their diameters, evaluated the in vitro release of PGE(2), using enzyme immunoassay and MS uptake by peritoneal macrophages. To assess the preservation of biological activities of this mediator, we determined the effect of PGE(2) released from MS on LPS-induced TNF-alpha release by murine peritoneal macrophages. We also analyzed the effect of encapsulated PGE(2) on inflammatory mediators release from HUVECs. Finally, we studied the effect of PGE(2) released from biodegradable MS in sepsis animal model. The use of this formulation can provide an alternative strategy for treating infections, by modulating or inhibiting inflammatory responses, especially when they constitute an exacerbated profile. (C) 2008 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 05/00110-4 - Estudos sobre os efeitos da administração de microesferas de leucotrieno B4 e prostaglandina E2 em modelo de histoplasmose murina
• Beneficiário: Roberto Nicolete
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 02/12856-2 - Modulação das respostas imunes inata e adquirida por leucotrienos e prostaglandinas
• Beneficiário: Lúcia Helena Faccioli
• Modalidade de apoio: Auxílio à Pesquisa - Temático